Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost adults can stay on weight loss injections for as long as they remain clinically suitable and continue to benefit from treatment. There is no fixed universal time limit written into the licences for Mounjaro or Wegovy, but your prescriber will review whether continuing makes sense at every stage. These are prescription-only medicines, and that clinical review is not a formality. The honest answer is: it depends on which medicine you're taking, what the evidence says, and what your individual circumstances look like.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is a question our prescribers hear most weeks, and the answer is more nuanced than many people expect. Mounjaro's UK product licence does not specify a maximum treatment duration. Clinical trials ran for 72 weeks and showed continued weight reduction throughout, but real-world prescribing can extend beyond that period, subject to ongoing review. If you're asking how long you can take weight loss injections without a fixed endpoint in mind, the short answer for tirzepatide is: there isn't one written into the licence.
Wegovy's position is slightly different in the NHS context. NICE's recommendation (TA875) specifies a maximum of two years when semaglutide is used within an NHS specialist weight management service. That two-year cap is part of the NHS commissioning guidance, not the medicine's licence itself. Private prescribing is governed by the SmPC, which does not impose the same ceiling. That distinction matters if you're weighing up your options, and the range of weight loss injections available in the UK each carry their own guidance on this.
In practice, how long you stay on either injection depends on three things: whether you're still losing weight or maintaining a meaningful reduction, whether side effects remain manageable, and whether your prescriber judges that the benefits outweigh any risks at each review. That assessment happens at every repeat order, not just at the start.
This is where the evidence gets important. Clinical trial data for both tirzepatide and semaglutide consistently shows that a significant proportion of lost weight returns when treatment is stopped. In STEP 1, participants who discontinued semaglutide regained most of the weight they had lost within a year. The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed a similar pattern in extension analyses.
This doesn't mean everyone needs to stay on injections indefinitely. Some people make lasting changes to how they eat and move during treatment, and those habits reduce regain risk. Others find that stopping prompts a rapid return of appetite and weight. Neither outcome is a moral failing; it reflects the biology of appetite regulation. Weight is shaped by hormones and physiology, not willpower alone.
Understanding this is part of why the question of how long to stay on weight loss injections should involve your prescriber directly. A plan to stop treatment gradually, with lifestyle support in place, produces better outcomes than an abrupt stop. And some people, after discussion with their clinician, decide that long-term or indefinite treatment is the right choice for them. That is a legitimate clinical decision, not a shortcut.
Neither Mounjaro nor Wegovy is designed to be taken forever without reassessment. The NICE guidance for tirzepatide (TA1026) notes that if a person loses less than five percent of their body weight after six months at their highest tolerated dose, continuing should be reviewed. That threshold applies to NHS prescribing, but it reflects a sensible principle that applies privately too: if a medicine is not producing meaningful benefit, the case for continuing weakens.
At nume, every repeat order goes through a clinical review by a GPhC-registered prescriber — not an automated process. A real clinician looks at your progress before a further supply is issued. You can read more about how long you can be on weight loss injections and how reviews work in practice, or explore the wider landscape of weight loss treatment options if you're still deciding which route makes sense. For context on what treatment typically involves financially, the treatment page sets out what's included in each order.
The NHS page on tirzepatide also covers the practicalities of ongoing use in plain language, including what to discuss with your healthcare provider if your circumstances change.
Possibly, yes. There is no evidence that long-term use of licensed GLP-1 medicines at appropriate doses causes harm that would rule out extended treatment as a category. The question of whether staying on weight loss injections for life is realistic is one more people are now asking seriously, and clinicians are taking it seriously too, particularly as services like our weight loss injections clinic in Cardiff see growing numbers of patients considering exactly that conversation.
What the current evidence cannot tell us definitively is what happens over decades, because the longest trials have run for a few years. Ongoing post-marketing surveillance, including the MHRA's monitoring programmes, will add to that picture over time. For now, the position is: extended use is clinically supported where benefit continues and side effects are acceptable, and the decision is made with a prescriber, not unilaterally.
If you are thinking about long-term use and want to talk through your personal situation, the starting point is always a clinical consultation. Speak to our prescribers, and they will give you an honest view based on your health history rather than a one-size answer.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.